Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.

Autor: Kawachi H; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Kunimasa K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Kukita Y; Laboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Japan., Nakamura H; Laboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Japan., Honma K; Department of Diagnostic Pathology & Cytology, Osaka International Cancer Institute, Osaka, Japan., Kawamura T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Inoue T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Tamiya M; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Kuhara H; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Nishino K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Mizote Y; Department of Cancer Drug Discovery & Development, Osaka International Cancer Institute, Osaka, Japan., Akazawa T; Department of Cancer Drug Discovery & Development, Osaka International Cancer Institute, Osaka, Japan., Tahara H; Department of Cancer Drug Discovery & Development, Osaka International Cancer Institute, Osaka, Japan.; Project Division of Cancer Biomolecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Kumagai T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Jazyk: angličtina
Zdroj: Immunotherapy [Immunotherapy] 2021 Jul; Vol. 13 (10), pp. 799-806. Date of Electronic Publication: 2021 May 25.
DOI: 10.2217/imt-2020-0311
Abstrakt: SMARCA4-deficient thoracic sarcoma (DTS) is a recently noted progressive thoracic malignancy. We recently experienced three cases of SMARCA4-DTS who were treated with atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (ABCP) as the first-line therapy. Immunohistopathological analysis revealed absent expression of SMARCA4 in all cases. The tumor mutational burden was over 11/Mb and mutations in SMARCA4 and TP53 were detected in all three cases. Partial response to ABCP treatment was observed in all three cases, with a progression-free survival of approximately 6 months or longer and a continuous response of 1 year or longer in one case. The first-line ABCP treatment demonstrated durable efficacy in SMARCA4-DTS regardless of the degree of PD-L1 expression.
Databáze: MEDLINE
Externí odkaz: